Pancreatic Cancer Drug Resistance Mechanisms Uncovered
Pancreatic cancer cells typically rely on a mutant version of the KRAS protein to proliferate. These cancer cells can also survive losing KRAS by activating alternative growth pathways. CSHL scientists discovered a new interaction between mutant KRAS and a protein complex called RSK1/NF1 that may be the source of this adaptive resistance.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed